Survey explores new risks in changing biopharma landscape

MilliporeSigma has unveiled survey results of 250 global biopharmaceutical executives on how their companies will manage new risks created by the fast-changing biopharmaceutical landscape.

The survey, which was sponsored by MilliporeSigma, was conducted by leading research group the Economist Intelligence Unit (EIU).
“In response to the uncertainty and disruption facing the biopharmaceutical industry, MilliporeSigma has moved beyond old risk-management models and has adopted and is applying new strategies at the earliest stages of development and seeing them through to commercialisation,” explained Udit Batra, Member, Executive Board, Merck KGaA, Darmstadt, Germany and CEO, MilliporeSigma.
MilliporeSigma revealed the findings at the BIO International Convention, in San Francisco, California on June 8th, 2016.
Key study highlights include:

• 48% of respondents are developing or are set to develop novel therapies including gene and cell therapies
• Over the next five years biopharmas expected to enter into South Korea, Indonesia and Taiwan
• 32% feared regulatory uncertainty could unsettle their strategy over the next five years
• 80% remained highly optimistic about their company’s ability to bring new drug products to market over the next five years

Download the report

To download the report and access additional content on the changing nature of biopharma, visit www.gobeyondbiopharma.com

Author

Phill Allen

Managing Director

Phill is an innovative thinker particularly in fluid management. His expertise lies in ensuring the seamless flow of pharmaceutical liquid logistics, whether it's optimising current processes or pioneering new approaches.

Follow me